Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 8/20 | 0.69 |
| ▸ | LATS2 | Q9NRM7 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | PDE5A | O76074 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | PRKCH | P24723 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604895 | 0.88 | LATS1 (0.71) | LATS1LATS2MEN1KMT2APDE5A | |
| SCHEMBL7607826 | 0.88 | LATS1 (0.71) | LATS1LATS2MEN1KMT2APDE5A | |
| SCHEMBL7613487 | 0.88 | PDE5A (0.65) | LATS1PDE5AKDM4ELMNAPKM | |
| SCHEMBL7609033 | 0.87 | LATS1 (0.69) | LATS1LATS2MEN1KMT2APDE5A | |
| SCHEMBL7606480 | 0.87 | LATS1 (0.69) | LATS1LATS2MEN1KMT2APDE5A | |
| SCHEMBL7607906 | 0.86 | LATS1 (0.68) | LATS1LATS2MEN1KMT2AKDM4E | |
| SCHEMBL7607077 | 0.85 | LATS1 (0.67) | LATS1LATS2MEN1KMT2AKDM4E | |
| SCHEMBL7607940 | 0.84 | LATS1 (0.66) | LATS1LATS2MEN1KMT2AKDM4E | |
| SCHEMBL7615723 | 0.84 | LATS1 (0.66) | LATS1LATS2MEN1KMT2APDE5A | |
| SCHEMBL7607058 | 0.84 | LATS1 (0.66) | LATS1LATS2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | LATS1 674/4885LATS2 791/4885MEN1 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.